Patent ID: 11958908
Assignee: CRISPR THERAPEUTICS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 15:
16. A method of depleting a population of CD117+ cells in a patient comprising administering to the patient an antibody drug conjugate (ADC) represented by the formula Ab-Z-L-Am, wherein Ab is an antibody or antigen-binding fragment thereof that binds CD117, L is a linker, Z is a chemical moiety, and Am is an amatoxin, wherein the antibody or antigen-binding fragment thereof comprises:
(i) a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 145, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:153, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 3; and a light chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 154, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:149, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 155;
(ii) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 151, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 152;
(iii) a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 145, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 146, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 147; and a light chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 157, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 155;
(iv) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 143, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 156;
(v) a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 145, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:159, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 3; and a light chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 157, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 155;
(vi) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 158, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 156;
(vii) a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 145, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 3; and a light chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 154, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 149, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 155;
(viii) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 160, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 152;
(ix) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 98, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 102;
(x) a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 186, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 187; and a light chain variable region comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 188, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 149, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 189;
(xi) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 98, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 99;
(xii) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 99;
(xiii) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 100; or
(xiv) a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 98, and a light chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 101.